viral breakthrough

viral breakthrough

The ability of a virus, such as hepatitis C or HIV, to mutate into a drug-resistant form during treatment with antiviral drugs. The mutation becomes evident when concentrations of the virus reappear in the plasma of treated patients after initially becoming undetectable.
References in periodicals archive ?
Given the advancements in treatment, viral breakthrough is not uncommon.
Even within genotype 1, patients with subtype la infections have experienced a higher rate of drug resistance and viral breakthrough than subtype lb.
There were no cases of viral breakthrough during therapy, and HCV deep se-quencing in a subgroup of patients detected none of the genetic mutations known to be associated with resistance to sofosbuvir.
The cerebral vasoconstriction was associated with treatment intensification with peginterferon alfa and ribavirin following viral breakthrough in one patient.
All patients receiving 4 weeks of treatment with ACH-1625 demonstrated continuous and substantial declines in HCV RNA with no viral breakthrough during therapy at any of the doses.
Both viral breakthrough and genotypic resistance were significantly less common with telbivudine.
The secondary endpoint of combination therapy was prevention of viral breakthrough and emergence of resistant-type HBV.
This patient had a partial response to treatment but developed viral breakthrough and was discontinued.
No patients dropped out of the study because of drug-related events, and no cases of viral breakthrough or post-treatment relapse have been reported to date, Dr.
The study also found that in a GT1a prior null responder population, an interferon-free regimen of DCV, ASV 200 mg BID and ribavirin resulted in a high rate of viral breakthrough and did not warrant further investigation.
The Hemopurifier is also being offered as a salvage therapy to infected individuals who suffer a viral breakthrough during standard-of-care therapy.
Viral breakthrough rates during treatment were highest in the telaprevir/interferon-only group, at 21%, compared with 11%, 10%, and 3% in the T12/ PR24, T24/PR48, and PR48 groups.